S.T. Stent News
5 articles
growth-positive
New revolutionary device can improve outcome of sinus surgery
StStent, a medical device company, has developed a product called ArchSinus that can improve the healing process for patients suffering from chronic sinusitis who undergo functional endoscopic sinus surgery (FESS). The device has undergone successful clinical trials in Israel and the US, and the company expects to have several customers for the product by the end of the year. StStents latest funding round, launched using ExitValleys platform, has already reached 40% of its goal.
CustomersInvestment
growth-positive
S.T.Stent Keeps Sinus Cavity Supported Post Surgery for Nearly a Month
STS Medical, an Israeli company, has received FDA clearance for its S.T.Stent sinus stent. The device is used for the treatment of chronic sinusitis and other related conditions. It is flexible, conforms to the sinus cavity, and is designed to anchor in place. The device is made of biocompatible materials and can be left in the patients sinus cavity for up to four weeks. Removal is a simple in-office procedure. This FDA clearance is expected to have a positive impact on the growth of STS Medical.
Customers
growth-positive
Israeli startup gets FDA nod for stent to help sinusitis sufferers
The US Food and Drug Administration has approved a nasal implant developed by Israeli startup STS Medical Ltd. The implant is designed to reduce the need for operations for individuals with chronic sinusitis. The self-expanding tube, made of nitinol, prevents post-surgical complications such as inflammation and scarring. The company predicts that the implant will reduce the probability of additional surgical procedures by 50%. The implant is expected to be available in Israel within six months and in the US by the end of the year. Entellus Medical Inc., a US-based medical technology firm, has expressed interest in the product.
Customers
growth-positive
STS Medical Receives FDA Regulatory Clearance
STS Medical Ltd., a portfolio company of The Trendlines Group Ltd., has received regulatory clearance from the FDA for its composite sinus stent. The stent, developed by S.T.Stent, is designed to keep the sinus cavity open after Functional Endoscopic Sinus Surgery (FESS) to reduce the need for revision surgeries. The FDA clearance allows the company to market the product in the U.S. The company is well-positioned for commercialization and has received interest from potential partners and distributors. The stent can also be used for other conditions such as chronic allergic rhinitis. The article was published on January 8, 2018.
CustomersPartners
growth-positive
S.T. Stent Completes $450k Raise
S.T. Stent, a portfolio company of Trendlines Medical, has raised $450k in funding. They have developed a removable nasal stent for implantation following sinus surgery, which helps reduce the need for revision surgery. The funds raised will enable them to gain regulatory approval for their device.
Investment
